R-spondin-2 is a Wnt agonist that regulates osteoblast activity and bone mass
Open Access
- 14 August 2018
- journal article
- research article
- Published by Springer Nature in Bone Research
- Vol. 6 (1) , 1-14
Abstract
The R-spondin family of proteins are Wnt agonists, and the complete embryonic disruption of Rspo2 results in skeletal developmental defects that recapitulate the phenotype observed with Lrp5/6 deficiency. Previous work has shown that R-spondin-2 (Rspo2, RSPO2) is both highly expressed in Wnt-stimulated pre-osteoblasts and its overexpression induces osteoblast differentiation in the same cells, supporting its putative role as a positive autocrine regulator of osteoblastogenesis. However, the role of Rspo2 in regulating osteoblastogenesis and bone formation in postnatal bone has not been explored. Here we show that limb-bud progenitor cells from Rspo2 knockout mice undergo reduced mineralization during osteoblastogenesis in vitro and have a corresponding alteration in their osteogenic gene expression profile. We also generated the first Rspo2 conditional knockout (Rspo2floxed) mouse and disrupted Rspo2 expression in osteoblast-lineage cells by crossing to the Osteocalcin-Cre mouse line (Ocn-Cre + Rspo2f/f). Ocn-Cre + Rspo2f/f male and female mice at 1, 3, and 6 months were examined. Ocn-Cre + Rspo2f/f mice are decreased in overall body size compared to their control littermates and have decreased bone mass. Histomorphometric analysis of 1-month-old mice revealed a similar number of osteoblasts and mineralizing surface per bone surface with a simultaneous decrease in mineral apposition and bone formation rates. Consistent with this observation, serum osteocalcin in 3-month-old Ocn-Cre + Rspo2f/f was reduced, and bone marrow-mesenchymal stem cells from Ocn-Cre + Rspo2f/f mice undergo less mineralization in vitro. Finally, gene expression analysis and immunohistochemistry of mature bone shows reduced beta-catenin signaling in Ocn-Cre + Rspo2f/f. Overall, RSPO2 reduces osteoblastogenesis and mineralization, leading to reduced bone mass.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR069619, P30AR069620, R01AR066028, F31AR065858, F30AR071201)
This publication has 43 references indexed in Scilit:
- Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasisJournal of Clinical Investigation, 2017
- Recent advances in the management of osteoporosisF1000Research, 2017
- Stem Cell–Derived Endochondral Cartilage Stimulates Bone Healing by Tissue TransformationJournal of Bone and Mineral Research, 2013
- ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive mannerNature, 2012
- R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesisDevelopment, 2008
- Canonical and non‐canonical wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cellsJournal of Cellular Physiology, 2007
- Dynamic expression of R-spondin family genes in mouse developmentGene Expression Patterns, 2007
- Mutations in the Gene Encoding the Wnt-Signaling Component R-Spondin 4 (RSPO4) Cause Autosomal Recessive AnonychiaThe American Journal of Human Genetics, 2006
- Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptorJournal of Cell Biology, 2002
- LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye DevelopmentCell, 2001